Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertion mutations within the tyrosine kinase domain of EGFR.

被引：0
|
作者：
Costa, Daniel Botelho
Yasuda, Hiroyuki
Sng, Natasha J.
Yeo, Wee-Lee
de Figueiredo-Pontes, Lorena Lobo
Tenen, Daniel G.
Kobayashi, Susumu
机构：
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7523
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sensitivity of EGFR exon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR
    Yasuda, Hiroyuki
    Sng, Natasha J.
    Yeo, Wee-Lee
    Figueiredo-Pontes, Lorena L.
    Kobayashi, Susumu
    Costa, Daniel B.
    [J]. CANCER RESEARCH, 2012, 72
  • [2] SENSITIVITY OF EGFR EXON 20 INSERTION MUTATIONS TO EGFR INHIBITORS IS DETERMINED BY THEIR LOCATION WITHIN THE TYROSINE KINASE DOMAIN OF EGFR
    Yasuda, Hiroyuki
    Figueiredo-Pontes, Lorena L. D.
    Tenen, Daniel G.
    Kobayashi, Susumu
    Costa, Daniel B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S107 - S107
  • [3] Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
    Le, X.
    Robichaux, J. P.
    Nilsson, M. B.
    Ramaswamy, V.
    Ravichandran, A.
    Wu, J.
    Elamin, Y. Y.
    Hong, L.
    Udagawa, H.
    Socinski, M.
    Bhat, G.
    Lebel, F.
    Vincent, S.
    Bunn, V.
    Su, Z.
    Lawson, J.
    Cross, J.
    Heymach, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [4] EGFR mutations and EGFR tyrosine kinase inhibitors
    Torri, Valter
    Broggini, Massimo
    Garassino, Marina Chiara
    [J]. LANCET ONCOLOGY, 2015, 16 (07): : 746 - 748
  • [5] Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer
    Park, Siyeon
    Park, Seongyeol
    Kim, Tae Min
    Kim, Soyeon
    Koh, Jaemoon
    Lim, Joonoh
    Yi, Kijong
    Yi, Boram
    Ju, Young Seok
    Kim, Miso
    Keam, Bhumsuk
    Kim, Jung Sun
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Kim, Young Tae
    Heo, Dae Seog
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [6] Analysis of 142 lung carcinomas for mutations in the tyrosine kinase domain of EGFR.
    Rohlfs, E. M.
    Payeur, T. L.
    Rosenblum-Vos, L.
    Ross-Wiley, S.
    Sirko-Osadsa, D. A.
    Teicher, J.
    Allitto, B. A.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (05): : 663 - 663
  • [7] Discovery of selective and potent EGFR kinase inhibitors for exon20 insertion mutations
    Kim, Sunghwan
    Lee, Younho
    Kim, Hwan
    Kang, Juhee
    Seok, Jiyoon
    Seo, Kyung-Ah
    Ahn, Jaeyoung
    Kang, Hee-Bum
    Lee, Sun-Hwa
    Son, Jung Beom
    Choi, Hwan Geun
    Kim, Nam Doo
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [8] Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
    Kobayashi, Susumu
    Canepa, Hannah M.
    Bailey, Alexandra S.
    Nakayama, Sohei
    Yamaguchi, Norihiro
    Goldstein, Michael A.
    Huberman, Mark S.
    Costa, Daniel B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) : 118 - 122
  • [9] Comparison of various EGFR tyrosine kinase inhibitors (TKIs) for tumors with exon 18 mutations of the EGFR gene
    Mitsudomi, Tetsuya
    Kobayashi, Yoshihisa
    Togashi, Yosuke
    Mizuuchi, Hiroshi
    Suda, Kenichi
    NIshio, Kazuto
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 83 - 83
  • [10] Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
    Passaro, Antonio
    Mok, Tony
    Peters, Solange
    Popat, Sanjay
    Ahn, Myung-Ju
    de Marinis, Filippo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 764 - 773
12345